A Single-arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients with Advanced Colorectal Cancer
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307) for treatment of patients with Advanced Colorectal Cancer,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).
• Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol;
• Age 18 to 70 years old;
• Advanced Colorectal Cancer that progresses after first-line chemotherapy；
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
• Expected survival time of ≥ 12 weeks;
• Good function of vital organs;
• Subjects entering this study due to disease progression must have an imaging record of disease progression before tumor sampling;
• At least one measurable target lesion that meets the definition of RECIST v1.1 after tumor sampling.